Thought Leader Insight & Analysis Report Anticoagulants Q3 2011

Medpredict, August 2011, Pages: 148

This report reviews the key competitive dynamics taking place in the antiplatelets and antithrombotics (anticoagulants) categories. We interviewed six internationally recognized experts for this panel and bring together their perspectives, opinions and predictions on:

- Burgeoning competition between Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and pipeline competitors Lixiana (edoxaban) and betrixaban; in SPAF, ACS, cancer, VTE/PE, mechanical valves. Formulary considerations / SPAF pharmacoeconomics.

- Competition between Brilinta (ticagrelor), Effient (prasugrel), Plavix (clopidogrel) and pipeline competitors elinogrel, vorapaxar, atopaxar and cangrelor. Formulary considerations.

- Acute and chronic treatment of ACS patients; with antiplatelet +/- antithrombotics.

Executive Summary

Report Highlights
- Antiplatelets
- Antithrombotics / Anticoagulants

Key Findings

Antiplatelets
- Formulary Considerations
- Plavix (Clopidogrel; Bms)
- Brilinta (Ticagrelor; Astra-Zeneca)
- Effient (Prasugrel; Lilly / Daiichi-Sankyo)
- Elinogrel (Portola / Novartis)
- Vorapaxar (Merck)
- Atopaxar (Eisai)
- Cangrelor (The Medicines Company)

Antithrombotics / Anticoagulants
- Spaf Pharmacoeconomics
- Role Of Antithrombotics In Acs
- Therapeutics
- Pradaxa (Dabigatran; Boehringer-Ingelheim)
- Xarelto (Rivaroxaban; Bayer-Schering / J&J)
- Eliquis (Apixaban; Bristol-Myers Squibb / Pfizer)
- Lixiana (Edoxaban; Daiichi-Sankyo)
- Betrixaban (Portola)
- Fxa Antidote (Portola)
- Lovenox (Enoxaparin; Sanofi-Aventis)
- Otamixaban (Sanofi-Aventis)

Thought-Leader Discussions
- Interview Cv02584
- Interview Cv02585
- Interview Cv02586
- Interview Cv02587
- Interview Cv02588
- Interview Cv02589

Customers who bought this item also bought

• Thought Leader Insight & Analysis Report - Cardiovascular Q4 2011
• Thought Leader Insight & Analysis Report: Anticoagulants Q2 2010
• Analysis of the Anticoagulant Market
• Acute Coronary Syndrome (Event Driven)
• Venous Thromboembolism (Event Driven)
• Atrial Fibrillation (Event Driven)
• Global Biopharma Outlook 2012 - Major US and EU Pharma
• Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma
• New Therapeutic Agents in Thrombosis and Thrombolysis. Edition No. 3. Fundamental and Clinical Cardiology
• Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011